Clinical Trials Browser

Phase 2 × Triple Negative Breast Neoplasms × tocilizumab × Clear all

NCT05846789 2026-01-21

SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms